{"id":30420,"date":"2024-11-25T17:26:35","date_gmt":"2024-11-25T11:56:35","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30420"},"modified":"2025-09-26T11:01:05","modified_gmt":"2025-09-26T05:31:05","slug":"5-emerging-cell-and-gene-therapies-for-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease","title":{"rendered":"5 Emerging Cell and Gene Therapies That Could Revolutionize Parkinson\u2019s Disease Treatment"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fa7adab4a46\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fa7adab4a46\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease\/#5_Emerging_Cell_and_Gene_Therapies_on_the_Horizon\" >5 Emerging Cell and Gene Therapies on the Horizon<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease\/#MeiraGTxs_AAV-GAD\" >MeiraGTx\u2019s AAV-GAD<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease\/#Hope_Biosciences_HB-adMSCs\" >Hope Biosciences\u2019 HB-adMSCs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease\/#Sumitomo_Pharmas_CT1-DAP001DSP-1083\" >Sumitomo Pharma\u2019s CT1-DAP001\/DSP-1083<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease\/#Prevail_TherapeuticsEli_Lillys_PR001_LY3884961\" >Prevail Therapeutics\/Eli Lilly\u2019s PR001 (LY3884961)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease\/#BlueRock_Therapeutics_Bemdaneprocel_BRT-DA01\" >BlueRock Therapeutics\u2019 Bemdaneprocel (BRT-DA01)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease\/#Future_Outlook_of_Cell_and_Gene_Therapies_in_Parkinsons_Disease_Treatment\" >Future Outlook of Cell and Gene Therapies in Parkinson\u2019s Disease Treatment<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Cell and gene therapies are transforming Parkinson&#8217;s treatment, bringing new hope to patients who previously had few options. While traditional approaches focus on symptom management, these advanced therapies target the underlying causes of the disease. By introducing healthy cells or repairing faulty genes, researchers are pioneering solutions that could slow, stop, or potentially reverse Parkinson&#8217;s progression. This era of precision medicine is expanding the limits of what was once believed achievable, envisioning a future where Parkinson&#8217;s no longer controls patients\u2019 lives.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-5-emerging-cell-and-gene-therapies-on-the-horizon\"><span class=\"ez-toc-section\" id=\"5_Emerging_Cell_and_Gene_Therapies_on_the_Horizon\"><\/span><strong>5 Emerging Cell and Gene Therapies on the Horizon<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Cell and gene therapies are revolutionizing treatments for Parkinson\u2019s disease, offering new possibilities where traditional methods have struggled. By addressing Parkinson\u2019s at its genetic and cellular roots, these therapies hold the potential to slow, halt, or even reverse the progression of this challenging neurodegenerative condition. Cutting-edge technologies like CRISPR, along with regenerative cell therapies, are creating opportunities to repair or replace damaged neurons, which could restore motor function and significantly enhance patients\u2019 quality of life. The future of Parkinson\u2019s disease treatment is shifting from merely managing symptoms to directly targeting the disease itself.<\/p>\n\n\n\n<p>The promise of cell and gene therapies for Parkinson\u2019s is already evident in early-stage clinical trials, where initial results are inspiring optimism. As these treatments advance from research to clinical practice, they are transforming the approach to Parkinson\u2019s care from symptom relief to actual disease modification. Patients in these trials are experiencing improved motor function and quality of life, fueling enthusiasm among healthcare providers and scientists alike.<\/p>\n\n\n\n<p>The outlook for cell and gene therapies for Parkinson\u2019s disease is bright. The current <a href=\"https:\/\/www.delveinsight.com\/report-store\/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight\">cell and gene therapies in Parkinson\u2019s disease pipeline<\/a> is robust, featuring a range of emerging treatments such as MeiraGTx\u2019s <strong>AAV-GAD<\/strong>, Hope Biosciences\u2019 <strong>HB-adMSCs<\/strong>, Sumitomo Pharma\u2019s <strong>CT1-DAP001\/DSP-1083<\/strong>, Prevail Therapeutics\/Eli Lilly\u2019s <strong>PR001 (LY3884961)<\/strong>, and BlueRock Therapeutics\u2019 <strong>Bemdaneprocel (BRT-DA01)<\/strong>, among others. Now, let\u2019s take a look at the 5 most promising cell and gene therapies poised to reshape the Parkinson\u2019s disease treatment landscape.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-meiragtx-s-aav-gad\"><span class=\"ez-toc-section\" id=\"MeiraGTxs_AAV-GAD\"><\/span><strong>MeiraGTx\u2019s AAV-GAD<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>AAV-GAD is an experimental gene therapy aimed at reprogramming malfunctioning brain circuits by locally producing GABA, a neurotransmitter that can help restore normal activity in essential brain cells affected by any form of Parkinson\u2019s disease. This therapy is delivered in a single infusion through a minimally invasive procedure, utilizing a proprietary device from MeiraGTx. This device administers a tiny dose\u2014about one drop\u2014of the gene therapy solution directly into the subthalamic nucleus, a crucial regulator of the movement-related brain circuits.<\/p>\n\n\n\n<p>Recently in October 2024, MeiraGTx reported top-line results from its clinical bridging study, MGT-GAD-025, which investigates AAV-GAD as a <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\">treatment for Parkinson\u2019s disease<\/a>. The MGT-GAD-025 study is a six-month, randomized, three-arm, double-blind, sham-controlled trial utilizing the AAV-GAD drug, produced by MeiraGTx at its in-house facilities with their commercial-grade manufacturing process. Participants included individuals with idiopathic Parkinson&#8217;s disease who had shown a positive response to levodopa for at least a year and had a UPDRS Part 3 score of 25 or higher in the &#8220;off&#8221; state. Fourteen subjects were divided into three groups: high dose (n=5), low dose (n=5), and sham (n=4).<\/p>\n\n\n\n<p>Participants received either AAV-GAD infused bilaterally into the subthalamic nucleus or a sham procedure, with doses of 7.0\u00d710^10 vg (low dose) or 21\u00d710^10 vg (high dose) per treated individual. The study\u2019s primary focus was on the safety and tolerability of AAV-GAD, while exploratory efficacy endpoints included the mean change in MDS-UPDRS Part 3 motor scores in the \u201coff\u201d state and quality of life as measured by the PDQ-39 from baseline to Week 26. Subjects completing this study are eligible to enroll in a long-term follow-up study (NCT05894343) for extended monitoring over five years post-treatment.<\/p>\n\n\n\n<p>MeiraGTx acquired this product from Vector Neurosciences. Currently, the therapy is in <strong>Phase II<\/strong> clinical development for Parkinson\u2019s disease. AAV-GAD stands out as the first gene therapy for Parkinson\u2019s disease featuring an objective imaging biomarker that aligns with clinical improvement.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hope-biosciences-hb-admscs\"><span class=\"ez-toc-section\" id=\"Hope_Biosciences_HB-adMSCs\"><\/span><strong>Hope Biosciences\u2019 HB-adMSCs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Hope Biosciences\u2019 HB-AdMSCs are mesenchymal stem cells derived from adipose (fat) tissue and refined using a proprietary cell culture platform. These pure mesenchymal stem cells, sourced from adult fat, are being developed as cell-based therapies for various conditions. Currently, Hope Bio is preparing cells for a Phase II Parkinson\u2019s disease clinical trial, authorized by the FDA and conducted by the Hope Biosciences Stem Cell Research Foundation (HBSCRF), to evaluate the safety and effectiveness of repeated intravenous infusions of autologous adipose-derived mesenchymal stem cells in enhancing daily functioning and quality of life in individuals with Parkinson\u2019s Disease. This randomized <strong>Phase II study<\/strong> aims to compare the safety and efficacy of multiple infusions of allogeneic HB-adMSCs against a placebo for <a href=\"https:\/\/www.delveinsight.com\/report-store\/cell-and-gene-therapy-in-parkinson-disease\">Parkinson\u2019s treatment<\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-sumitomo-pharma-s-ct1-dap001-dsp-1083\"><span class=\"ez-toc-section\" id=\"Sumitomo_Pharmas_CT1-DAP001DSP-1083\"><\/span><strong>Sumitomo Pharma\u2019s CT1-DAP001\/DSP-1083<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>DSP-1083 is currently in the Phase I\/II stage of development for the treatment of Parkinson&#8217;s disease. It consists of dopamine neural progenitor cells derived from induced pluripotent stem cells (iPS cells) and is administered orally. The cell therapy is transplanted into Parkinson\u2019s disease patients to alleviate neurological symptoms by providing dopamine, which is secreted and supplemented by the transplanted cells. These progenitor cells are derived from human induced pluripotent stem cells.<\/p>\n\n\n\n<p>In March 2024, Sumitomo Pharma announced that the FDA had cleared its Investigational New Drug (IND) Application for a clinical trial using iPS cell-derived dopaminergic progenitor cells to treat Parkinson\u2019s disease. The IND, submitted in February 2024, received FDA approval following a 30-day review, and preparations for the study are now underway. Cryopreserved cells will be used in the trial.<\/p>\n\n\n\n<p>Additionally, an investigator-initiated study using non-cryopreserved cells began at the University of California San Diego School of Medicine in November 2023, while Kyoto University Hospital has been conducting a similar study in Japan since 2018.<\/p>\n\n\n\n<p>This marks Sumitomo Pharma\u2019s first clinical trial in the US to use allogeneic iPS cell-derived differentiated cells in the regenerative medicine and cell therapy field, which is a key focus for the company. It represents a significant step in advancing its business in this area in the US.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"443\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease-1024x443.png\" alt=\"Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease\" class=\"wp-image-30336\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease-1024x443.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease-300x130.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease-150x65.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease-768x332.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease-1536x664.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease.png 1600w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-prevail-therapeutics-eli-lilly-s-pr001-ly3884961\"><span class=\"ez-toc-section\" id=\"Prevail_TherapeuticsEli_Lillys_PR001_LY3884961\"><\/span><strong>Prevail Therapeutics\/Eli Lilly\u2019s PR001 (LY3884961)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>PR001 is being developed as a potential disease-modifying, single-dose gene therapy for individuals with Parkinson&#8217;s disease associated with GBA1 mutations (PD-GBA). PD-GBA is caused by mutations in the GBA1 gene, which provides the instructions for producing the lysosomal enzyme beta-glucocerebrosidase (GCase). GCase is essential for breaking down and recycling glycolipids, a type of cellular component that tends to accumulate with age. PD-GBA patients have a mutation in one copy of the GBA1 gene.&nbsp;<\/p>\n\n\n\n<p>When GCase levels are insufficient, glycolipids build up, leading to lysosomal dysfunction and the aggregation of \u03b1-Synuclein protein in cells. This accumulation is believed to trigger the inflammation and neurodegeneration associated with PD-GBA and the symptoms of Gaucher disease. PR001 uses the well-established AAV9 viral vector to deliver a healthy copy of the GBA1 gene and is currently being evaluated in <strong>Phase I\/II PROPEL clinical trial<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-bluerock-therapeutics-bemdaneprocel-brt-da01\"><span class=\"ez-toc-section\" id=\"BlueRock_Therapeutics_Bemdaneprocel_BRT-DA01\"><\/span><strong>BlueRock Therapeutics\u2019 Bemdaneprocel (BRT-DA01)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Bemdaneprocel (BRT-DA01) is an experimental cell therapy aimed at replacing the dopamine-producing neurons lost in Parkinson\u2019s disease. The dopaminergic neuron precursors used in this therapy are derived from human embryonic stem cells. During a surgical procedure, these neuron precursors are transplanted into the brain of a Parkinson\u2019s patient. Once implanted, they have the potential to rebuild damaged neural networks and help restore both motor and non-motor functions. However, Bemdaneprocel has not yet been approved by any health authority for the treatment of any disease or medical condition.<\/p>\n\n\n\n<p>In May 2024, BlueRock Therapeutics announced that its investigational therapy, bemdaneprocel, for <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-pipeline-insights\">treating Parkinson\u2019s disease<\/a> received <strong>Regenerative Medicine Advanced Therapy (RMAT) designation<\/strong> from the FDA. Earlier, in March 2024, the company shared 18-month data from a <strong>Phase I clinical trial<\/strong> of bemdaneprocel. These findings were presented at the <strong>Alzheimer\u2019s and Parkinson\u2019s Diseases Conference in Lisbon, Portugal<\/strong>.<\/p>\n\n\n\n<p>The results show that after 18 months, bemdaneprocel remains well tolerated, with no significant safety concerns. Transplanted cells survive and engraft in the brain, and the F-DOPA signal continues to rise even after immune suppression therapy was halted at 12 months, as per the study\u2019s protocol.<\/p>\n\n\n\n<p>Furthermore, exploratory clinical endpoints showed improvements compared to baseline in both patient cohorts, with those receiving a higher dose showing greater progress than those receiving a lower dose. These improvements were measured using the MDS-Unified Parkinson\u2019s Disease Rating Scale Part III (MDS-UPDRS Part III) and the Hauser Diary, both of which assess the severity of motor symptoms in Parkinson\u2019s disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-outlook-of-cell-and-gene-therapies-in-parkinson-s-disease-treatment\"><span class=\"ez-toc-section\" id=\"Future_Outlook_of_Cell_and_Gene_Therapies_in_Parkinsons_Disease_Treatment\"><\/span><strong>Future Outlook of Cell and Gene Therapies in Parkinson\u2019s Disease Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The future of <a href=\"https:\/\/www.delveinsight.com\/report-store\/cell-and-gene-therapy-in-parkinson-disease\">cell and gene therapies in Parkinson\u2019s disease treatment<\/a> is poised for significant advancements, with the potential to transform the landscape of care for patients. As research in regenerative medicine continues to progress, cell-based therapies, such as stem cell transplantation, hold promise for replacing damaged neurons and restoring motor function. Recent studies have explored the use of induced pluripotent stem cells (iPSCs) and fetal-derived dopaminergic neurons, which could help replace the lost dopamine-producing cells in the brain. These therapies aim to address the root causes of Parkinson\u2019s disease, offering hope for long-term symptom relief and even the possibility of disease modification, rather than merely managing symptoms. Clinical trials have shown some encouraging results, though challenges remain regarding the safety, integration, and functionality of transplanted cells.<\/p>\n\n\n\n<p>Gene therapies also offer a promising avenue for treating Parkinson\u2019s disease by targeting the genetic and molecular mechanisms underlying the disorder. Approaches such as delivering genes that encode for neuroprotective factors, like glial cell-derived neurotrophic factor (GDNF), or correcting mutations in specific genes (e.g., LRRK2, PARK7) may slow disease progression or provide symptomatic relief. Advancements in viral vector technology, such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/adeno-associated-virus-vectors-in-gene-therapy-market\">adeno-associated virus (AAV) vectors<\/a>, have enabled more precise and efficient gene delivery to the brain. With the increasing success of these technologies in preclinical and early-stage clinical trials, gene therapies will likely become an integral part of personalized treatment regimens for Parkinson\u2019s disease in the coming years. However, overcoming challenges related to delivery methods, long-term effects, and regulatory hurdles will be key to realizing the full potential of these therapies.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/cell-and-gene-therapy-in-parkinson-disease\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook-1024x194.png\" alt=\"Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook\" class=\"wp-image-30334\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><strong>Frequently Asked Questions<\/strong><\/p>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1758864603571\"><strong class=\"schema-faq-question\"><strong>What are some of the promising cell and gene therapies currently in development for Parkinson\u2019s disease?<\/strong><\/strong> <p class=\"schema-faq-answer\">Emerging therapies include MeiraGTx\u2019s AAV-GAD, Hope Biosciences\u2019 HB-adMSCs, Sumitomo Pharma\u2019s CT1-DAP001\/DSP-1083, Prevail Therapeutics\/Eli Lilly\u2019s PR001 (LY3884961), and BlueRock Therapeutics\u2019 Bemdaneprocel (BRT-DA01).<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758864610918\"><strong class=\"schema-faq-question\"><strong>How does AAV-GAD from MeiraGTx aim to treat Parkinson\u2019s disease?<\/strong><\/strong> <p class=\"schema-faq-answer\">AAV-GAD uses a viral vector to deliver a gene that helps produce GABA, a neurotransmitter. It\u2019s infused into the subthalamic nucleus and is designed to normalize malfunctioning brain circuits. Early trials focus on safety and motor improvements.\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758864622925\"><strong class=\"schema-faq-question\"><strong>What makes PR001 (LY3884961) different and in which patient segment is it being tested?<\/strong><\/strong> <p class=\"schema-faq-answer\">PR001 is a single-dose gene therapy targeting the GBA1 mutation (PD-GBA subtype). It delivers a healthy copy of the GBA1 gene using AAV9 to treat patients with that specific genetic mutation. The approach is aimed at disease modification rather than symptom suppression.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758864629519\"><strong class=\"schema-faq-question\"><strong>What are the main market drivers for cell and gene therapies in Parkinson\u2019s disease?<\/strong><\/strong> <p class=\"schema-faq-answer\">Drivers include the high unmet need beyond symptom management, advances in viral vector technology, regenerative medicine, and patient demand for treatments that can slow or reverse neurodegeneration. Regulatory incentives for advanced therapies also help.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758864642453\"><strong class=\"schema-faq-question\"><strong>What obstacles or barriers could delay or limit the success of these emerging Parkinson\u2019s therapies?<\/strong><\/strong> <p class=\"schema-faq-answer\">Challenges include long clinical development timelines, safety risks (such as immune reactions and integration issues), ensuring durable effects, delivery across brain barriers, regulatory hurdles, and the high cost of manufacturing and commercialization.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cell and gene therapies are transforming Parkinson&#8217;s treatment, bringing new hope to patients who previously had few options. While traditional approaches focus on symptom management, these advanced therapies target the underlying causes of the disease. By introducing healthy cells or repairing faulty genes, researchers are pioneering solutions that could slow, stop, or potentially reverse Parkinson&#8217;s [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":30422,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[16778,19134,19133,19131,22360],"industry":[17225],"therapeutic_areas":[17235,17245],"class_list":["post-30420","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-parkinsons-disease-4","tag-parkinsons-disease-clinical-trials","tag-parkinsons-disease-pipeline","tag-parkinsons-disease-treatment","tag-parkinsons-disease-cell-and-gene-therapy","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>5 Promising Cell and Gene Therapies for Parkinson\u2019s Disease<\/title>\n<meta name=\"description\" content=\"Cell and gene therapies revolutionizing treatments for Parkinson\u2019s disease, offering new possibilities where traditional methods struggled.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"5 Promising Cell and Gene Therapies for Parkinson\u2019s Disease\" \/>\n<meta property=\"og:description\" content=\"Cell and gene therapies revolutionizing treatments for Parkinson\u2019s disease, offering new possibilities where traditional methods struggled.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-25T11:56:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-26T05:31:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/25171402\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"5 Promising Cell and Gene Therapies for Parkinson\u2019s Disease","description":"Cell and gene therapies revolutionizing treatments for Parkinson\u2019s disease, offering new possibilities where traditional methods struggled.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease","og_locale":"en_US","og_type":"article","og_title":"5 Promising Cell and Gene Therapies for Parkinson\u2019s Disease","og_description":"Cell and gene therapies revolutionizing treatments for Parkinson\u2019s disease, offering new possibilities where traditional methods struggled.","og_url":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-11-25T11:56:35+00:00","article_modified_time":"2025-09-26T05:31:05+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/25171402\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease","url":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease","name":"5 Promising Cell and Gene Therapies for Parkinson\u2019s Disease","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/25171402\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease.png","datePublished":"2024-11-25T11:56:35+00:00","dateModified":"2025-09-26T05:31:05+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Cell and gene therapies revolutionizing treatments for Parkinson\u2019s disease, offering new possibilities where traditional methods struggled.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864603571"},{"@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864610918"},{"@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864622925"},{"@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864629519"},{"@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864642453"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/25171402\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/25171402\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease.png","width":466,"height":284,"caption":"5-emerging-cell-and-gene-therapies-for-parkinsons-disease"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864603571","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864603571","name":"What are some of the promising cell and gene therapies currently in development for Parkinson\u2019s disease?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Emerging therapies include MeiraGTx\u2019s AAV-GAD, Hope Biosciences\u2019 HB-adMSCs, Sumitomo Pharma\u2019s CT1-DAP001\/DSP-1083, Prevail Therapeutics\/Eli Lilly\u2019s PR001 (LY3884961), and BlueRock Therapeutics\u2019 Bemdaneprocel (BRT-DA01).","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864610918","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864610918","name":"How does AAV-GAD from MeiraGTx aim to treat Parkinson\u2019s disease?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"AAV-GAD uses a viral vector to deliver a gene that helps produce GABA, a neurotransmitter. It\u2019s infused into the subthalamic nucleus and is designed to normalize malfunctioning brain circuits. Early trials focus on safety and motor improvements.\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864622925","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864622925","name":"What makes PR001 (LY3884961) different and in which patient segment is it being tested?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"PR001 is a single-dose gene therapy targeting the GBA1 mutation (PD-GBA subtype). It delivers a healthy copy of the GBA1 gene using AAV9 to treat patients with that specific genetic mutation. The approach is aimed at disease modification rather than symptom suppression.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864629519","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864629519","name":"What are the main market drivers for cell and gene therapies in Parkinson\u2019s disease?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Drivers include the high unmet need beyond symptom management, advances in viral vector technology, regenerative medicine, and patient demand for treatments that can slow or reverse neurodegeneration. Regulatory incentives for advanced therapies also help.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864642453","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease#faq-question-1758864642453","name":"What obstacles or barriers could delay or limit the success of these emerging Parkinson\u2019s therapies?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Challenges include long clinical development timelines, safety risks (such as immune reactions and integration issues), ensuring durable effects, delivery across brain barriers, regulatory hurdles, and the high cost of manufacturing and commercialization.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/25171402\/5-emerging-cell-and-gene-therapies-for-parkinsons-disease-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s Disease Cell and Gene Therapy<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease<\/span>","<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease clinical trials<\/span>","<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease pipeline<\/span>","<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease treatment<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s Disease Cell and Gene Therapy<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 7 months ago"},"absolute_dates":{"created":"Posted on Nov 25, 2024","modified":"Updated on Sep 26, 2025"},"absolute_dates_time":{"created":"Posted on Nov 25, 2024 5:26 pm","modified":"Updated on Sep 26, 2025 11:01 am"},"featured_img_caption":"5-emerging-cell-and-gene-therapies-for-parkinsons-disease","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30420"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30420\/revisions"}],"predecessor-version":[{"id":33479,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30420\/revisions\/33479"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30422"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30420"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30420"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}